LifeMD Launches NavaMD

LifeMD, Inc., a leading direct-to-patient telehealth company, today announced the successful launch of NavaMD™.

LifeMD notes the NavaMD website went live at the end of the first quarter of fiscal 2021 and is the Company’s personalized tele-dermatology brand and clinic, offering services to patients across all 50 states.

Justin Schreiber, Chairman and CEO commented, “We are pleased to bring the NavaMD brand to life in 2021, as this will be LifeMD’s third successful brand launch in four years. We are an early mover in the $40 billion-dollar high growth direct-to-patient tele-dermatology space and are well-positioned to grow market share. By empowering patients seeking telehealth services, we feel that LifeMD is best positioned to actively bring about a sea change in both the convenience and accessibility by which patients receive personalized services and medications when needed. As such, we remain focused on refining customer acquisition strategies and building a de-risked brand portfolio that addresses low risk, massively underpenetrated and addressable markets such as the NavaMD clinical skincare offering.”

“By focusing on fast growing, therapeutic areas with high unmet needs, whose treatments are proven to be safe, we are creating the best runway for unrivaled growth in telehealth customer acquisition, recurring revenues and return on shareholder value,” mentioned Stefan Galluppi, Chief Technology Officer.

NavaMD’s services will be available to any patient seeking dermatology services. Service offerings include the diagnosis and treatment of prevalent skin conditions such as acne, rosacea, hyperpigmentation, signs of aging, and other prevalent skin conditions.

NavaMD’s customer acquisition strategy will be primarily set to growing its female customer base, fully supported by best-in-class direct response marketing, social media, and influencer campaigns.

Online medical treatment and services will be rendered through LifeMD’s network of U.S. licensed physicians, pharmacies, and, if appropriate, prescription oral and compounded topical medications to treat many common dermatological conditions.

In addition to the brand’s telemedicine offerings, NavaMD’s proprietary products leverage intellectual property and proprietary formulations licensed from Restorsea, a leading medical grade skincare technology platform. NavaMD is the first external provider to offer Restorsea’s patented medical-grade over-the-counter products for treating these prevalent skin conditions.

Like other LifeMD brands, NavaMD tele-dermatology services is highly personalized, powered by a proprietary technology stack. The engagement with patients is seamless and is driven by a simple three-step customer journey consisting of:

  1. Completing a free consultation: whereby a questionnaire and patient photo is submitted for review.
  2. Getting prescribed a custom formulated treatment regimen: NavaMD’s licensed U.S. doctors, and clinicians then work to design a custom prescription skincare treatment. A quick and convenient checkout process powered by LifeMD’s telehealth platform fills a prescription.
  3. The patient receives a personalized treatment by mail: LifeMD’s pharmacy services prepares and delivers a customer’s custom prescription treatment on a monthly recurring basis or as often as needed.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version